ABIOMED Selects Answerthink and SAP to Streamline Business Processes.

MIAMI -- Answerthink, Inc. (NASDAQ:ANSR), announced today that it has been selected by ABIOMED, Inc. (NASDAQ:ABMD) for the purchase, implementation, and support of EzLifeSciences, a mySAP(TM) All-in-One solution designed to streamline business processes and position the company for continued growth.

ABIOMED, headquartered in Danvers, MA, is a leading developer, manufacturer, and marketer of circulatory support technology for patients in heart failure. ABIOMED is currently the only company with FDA labeling on ventricular assist devices for all potentially recoverable acute heart failure indications. To date, more than 8,000 patients worldwide have been supported with ABIOMED devices including the AB5000(TM) Circulatory Support System and the BVS(R) 5000 Biventricular Support System. The company chose Answerthink based on the strength of its life sciences experience and its preconfigured solution built on the industry-leading mySAP software.

EzLifeSciences is an industry-specific offering from Answerthink based on best practices from SAP and customized for companies in the pharmaceutical and life sciences industries. It provides the benefits of a fixed-price, fixed-scope, fixed-timeline offering that is designed specifically to help life sciences companies achieve goals such as streamline new product development and automate processes required for FDA approvals and regulatory compliance.

ABIOMED is one of nine life sciences companies that have selected Answerthink and EzLifeSciences within the past year.

"We selected Answerthink and SAP in part because we liked Answerthink's business process focused methodology," said Daniel Lubin, Director of IT for ABIOMED. "Utilizing SAP to implement best practices, ABIOMED will obtain a fully validated system that is up and running faster, to enable powerful visibility into the critical operations of the business and enhance our business decision support capabilities."

According to John McGrath, Managing Director of Answerthink's SAP Solutions Group, "We're proud to have been selected by ABIOMED. SAP has been an exceptionally strong partner for us, and the combination of their powerful software with our best practices and industry expertise make this a unique offering for life sciences companies. It does more than just provide comprehensive integrated ERP functionality. It actually helps companies improve the efficiency and effectiveness of their operations at many different levels."

About Answerthink

Answerthink, Inc. (http://www.answerthink.com) is a leading business and technology consulting firm that enables companies to achieve world-class business performance. By leveraging the comprehensive database of The Hackett Group, Answerthink's business and technology solutions help clients significantly improve performance and maximize returns on technology investments. Answerthink's capabilities include benchmarking, business transformation, business applications, business intelligence, and offshore application development and support. Founded in 1997, Answerthink has offices throughout the United States and in Europe and India.

About ABIOMED

Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced "AB'-EE-O-MED") is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. ABIOMED currently manufactures and sells the AB5000(TM) Circulatory Support System and the BVS(R) 5000 Biventricular Support System for the temporary support of all patients with failing but potentially recoverable hearts. In Europe, ABIOMED offers the IMPELLA(R) RECOVER(R) minimally invasive cardiovascular support systems under CE Mark approval. The Company's AbioCor(R) Implantable Replacement Heart was the subject of an initial clinical trial under an Investigational Device Exemption from the United States Food and Drug Administration. The AbioCor has not been approved for commercial distribution, and is not available for use or sale outside of the initial clinical trial. For additional information please visit http://www.abiomed.com.

Copyright (C) 2006 SAP AG. All rights reserved.

SAP, R/3, mySAP, mySAP.com, xApps, xApp, SAP NetWeaver and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP AG in Germany and in several other countries all over the world. All other product and service names mentioned are the trademarks of their respective companies. Data contained in this document serves informational purposes only. National product specifications may vary.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risks, uncertainties and other factors that may cause Answerthink's actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statements. Factors that impact such forward-looking statements include, among others, the ability of the products, services, or practices mentioned in this release to deliver the desired effect, our ability to effectively integrate acquisitions into our operations, our ability to attract additional business, our ability to effectively market and sell our transformation advisory product offerings and other services, the timing of projects and the potential for contract cancellations by our customers, changes in expectations regarding the information technology industry, our ability to attract and retain skilled employees, possible changes in collections of accounts receivable, risks of competition, price and margin trends, changes in general economic conditions and interest rates as well as other risks detailed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2004 filed with the Securities and Exchange Commission. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.